BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
BTIG analyst Thomas Shrader initiates coverage on Serina Therapeutics (AMEX:SER) with a Buy rating and announces Price Target of $8.
BTIG analyst Thomas Shrader initiates coverage on Serina Therapeutics (AMEX:SER) with a Buy rating and announces Price Target of $8.